Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2024-07-01 00:00:00 ET · period of report 2024-07-01 · accession 0000950170-24-079666 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-07-01 | 2024-07-01 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $5.33 | +18.8K | 650.0K | +3% | +$100.1K |
| D | 2024-07-01 | 2024-07-01 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $0.00 | -18.8K | 288.5K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-01 | M | A | 18,773 | $5.33 | 649,959 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-07-01 | M | D | 18,773 | $0.00 | 288,456 | D | $5.33 · — to 2030-05-13 | 18,773 Common Stock | (F1) The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of May 14, 2020, subject to the reporting person's continued employment through each vesting date. |